SCOPE

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without overextending resources.

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, discusses how artificial intelligence/machine learning can help in areas such as feasibility, site selection, and patient recruitment.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Garty, chief technology officer, clinical data, provided his key takeaways from a panel he participated in on the growing interest around pragmatic studies.

Conference breakout session explores strategies for trial sites to strengthen patient relationships.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Tenaerts, chief scientific officer, Medable, highlights the recent findings and how decentralized elements can improve access to underrepresented populations.

In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: Ensuring Clinical Trial Success for Small Biopharma" session.

Conference breakout session examines the role of strategic partnerships in driving progress for sexual and gender minority inclusion in clinical research.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Davidson, vice president, product lead - sponsor tech strategy, Advarra, discussed ongoing challenges in study startup processes, including contract and budget issues, and feasibility concerns, which have persisted for over a decade.

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Norman, director, localization services, YPrime discussed how localization is becoming increasingly important as clinical trials become more global.

Conference keynote explores the long-term vision for integrating clinical research and care by 2035, including progress driven by digital advancements, artificial intelligence, and evolving regulatory frameworks.

Interactive panel on day 1 of SCOPE Summit 2025 highlighted the need for inclusive narratives, social listening to understand patient experiences, and the role of advocacy groups in opening doors to clinical trials.

This year’s submissions highlight initiatives around accelerating enrollment, personalizing recruitment, increasing diversity, and more.

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

Breakout session at SCOPE Summit 2024 discusses the potential use of artificial intelligence to improve clinical trial strategy generation.

Interactive panel at SCOPE discussed the potential of utilizing artificial intelligence in clinical trials.

A summary of this year’s key topics and discussions.

Highlights from the annual SCOPE conference held in Orlando, FL.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about concerns with clinical technology at the SCOPE 2023 conference in Orlando, FL.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about what should be top of mind for clinops professionals in 2023 at the SCOPE 2023 conference in Orlando, FL.

Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.

Sunny Kumar, MD, partner at GSR Ventures speaks about reducing hospital readmissions for high-risk patients at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about venture capital in clinical research at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education at CISCRP notes her key takeaways from the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP reveals what innovations are coming up at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP comments on current CISCRP happenings at the SCOPE 2023 conference in Orlando, FL.